Rare diseases
Investigational molecules
Locations
Recruiting trials first
6 clinical trials in this condition
FranceFrance
BelgiumFranceIn short
Gout is a painful form of arthritis that causes sudden attacks of joint pain and swelling. Managing this condition involves both treating acute flare-ups and preventing future episodes through medication and lifestyle changes.
Treating gout focuses on two main objectives that work together to improve quality of life. The first goal is to relieve the intense pain and swelling that occurs during acute attacks, also called gout flares. These episodes can strike suddenly, often waking people in the middle of the night with excruciating joint pain, most commonly in the big toe. The second goal is to lower uric acid levels in the blood over time to prevent future attacks and avoid long-term joint damage.
Treatment approaches vary depending on several factors. The stage of the disease matters—whether someone is experiencing their first attack or dealing with chronic gout with visible lumps under the skin called tophi (deposits of uric acid crystals). Individual patient characteristics also play an important role, including other health conditions like kidney disease, heart problems, or diabetes, as well as medications already being taken for other conditions. This is why two people with gout might receive different treatment plans.
There are established treatments that medical societies and doctors worldwide recognize as effective for gout. These standard approaches have been used for many years and their benefits are well understood. At the same time, researchers continue to explore new therapies through clinical trials, testing innovative medications and treatment strategies that may offer additional options for patients who don't respond well to current treatments or who experience troublesome side effects.
When a gout attack begins, quick action helps reduce pain and shorten the duration of symptoms. The main goal during an acute flare is to calm down the inflammation in the affected joint. Doctors typically prescribe one of three types of medications as first-line treatment: nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids (also called steroids).
NSAIDs are the most commonly used drugs for acute gout. These include over-the-counter options such as ibuprofen (Advil, Motrin) and naproxen sodium (Aleve), as well as stronger prescription NSAIDs like indomethacin (Indocin) or celecoxib (Celebrex). NSAIDs work by reducing inflammation and pain throughout the body. However, they can cause stomach upset, increase the risk of bleeding, and may not be suitable for people with kidney problems, heart disease, or stomach ulcers. It's important to note that aspirin should never be taken during a gout attack, as it can actually worsen the flare.
Colchicine is another medication used to treat acute attacks. It works differently from NSAIDs by interfering with the way white blood cells respond to uric acid crystals in the joint. Modern dosing of colchicine uses lower amounts than in the past—typically 1.2 mg followed by 0.6 mg one hour later—which reduces side effects while still providing relief. The most common side effects are gastrointestinal, including diarrhea, nausea, and abdominal cramping. Colchicine is most effective when taken within the first 24 hours of symptom onset.
Corticosteroids offer another option, particularly for patients who cannot take NSAIDs or colchicine due to other health conditions. These powerful anti-inflammatory medications can be given in several ways: as oral tablets like prednisone, as an injection directly into the affected joint, or as an intramuscular injection. Oral corticosteroids are typically prescribed at a dose of 30 to 40 mg daily, gradually reduced over 10 to 14 days. While effective, steroids can raise blood sugar levels in people with diabetes and may cause mood changes or sleep disturbances.
After treating the immediate pain of a gout attack, the focus shifts to preventing future episodes. This involves medications that lower the level of uric acid in the blood. These are called urate-lowering therapies or uric acid-lowering medications. The goal is to reduce uric acid levels below 6 mg/dL, which allows existing crystals to gradually dissolve and prevents new ones from forming.
The most commonly prescribed urate-lowering medication is allopurinol (Zyloprim). This drug works as a xanthine oxidase inhibitor, meaning it blocks an enzyme in the body that produces uric acid. Doctors typically start with a low dose of 100 mg or less per day, then gradually increase the dose every two to five weeks until the target uric acid level is reached. The maximum dose can go as high as 800 mg daily if needed. Starting slowly and adjusting carefully helps reduce the risk of triggering a gout flare when beginning treatment. Before starting allopurinol, patients of Southeast Asian or African American descent should be offered genetic testing for the HLA-B*5801 allele, as they have a higher risk of serious allergic reactions to the drug.
Febuxostat (Uloric) is another xanthine oxidase inhibitor that works similarly to allopurinol. It's typically started at 40 mg or less daily and can be increased to 80 mg daily. Febuxostat may be an option for people who cannot tolerate allopurinol, but studies have shown it carries an increased risk of cardiovascular problems and all-cause mortality. Because of this safety concern, doctors are cautious about prescribing it, especially for patients with existing heart disease.
Probenecid (Benemid) represents a different approach. Instead of reducing uric acid production, it helps the kidneys remove more uric acid through urine. This makes it a uricosuric agent. It's usually started at 100 mg once or twice daily and can be increased to 1000 mg twice daily. Probenecid is generally less effective than xanthine oxidase inhibitors and is not recommended for people with kidney problems.
For patients with severe gout who don't respond adequately to standard treatments, pegloticase (Krystexxa) offers a more intensive option. This medication is given as an intravenous infusion every two weeks at a dose of 8 mg. Pegloticase is a uricase enzyme that breaks down uric acid directly. It's typically reserved for patients with tophi or those who continue to have frequent attacks despite taking the highest tolerated doses of other medications. The treatment is expensive and carries risks of infusion reactions, so it's not used as a first-line therapy.
An important aspect of long-term gout management is recognizing that starting or adjusting urate-lowering medication can paradoxically trigger gout attacks. This happens because as uric acid levels drop, crystals that were stable in joints can shift and cause inflammation. To prevent this, doctors prescribe prophylactic (preventive) medication for the first three to six months after starting urate-lowering therapy. Low-dose colchicine, NSAIDs, or low-dose corticosteroids can all be used for this purpose. Recent guidelines suggest it's actually better to start urate-lowering therapy during an acute flare rather than waiting for it to resolve, as long as anti-inflammatory medication is also provided.
Urate-lowering therapy is typically a long-term commitment, often continuing for life. Studies have shown that when people with low uric acid levels stop their medication, 87% experience a gout flare within five years. This is because the underlying tendency to produce too much uric acid or eliminate too little doesn't go away. Maintaining consistent treatment helps keep uric acid levels controlled and prevents the return of painful attacks and joint damage.
Every medication carries potential side effects. NSAIDs can cause stomach pain, ulcers, kidney problems, and increased blood pressure. Colchicine commonly causes diarrhea and stomach upset. Corticosteroids can lead to weight gain, elevated blood sugar, mood changes, and weakened bones with long-term use. Allopurinol can cause skin rashes and, rarely, a serious allergic reaction called Stevens-Johnson syndrome. Febuxostat may increase cardiovascular risks. Pegloticase can cause infusion reactions and allergic responses. Patients should discuss these risks with their doctor and report any concerning symptoms promptly.
While standard treatments work well for many people with gout, researchers continue to investigate new approaches that might offer better results, fewer side effects, or options for patients who don't respond to current therapies. Clinical trials test these innovative treatments before they become widely available. Understanding what's being studied helps patients and doctors stay informed about potential future options.
One promising area of research focuses on more precisely targeting the inflammatory process that causes gout pain. Scientists have identified that a specific molecule called interleukin-1 (IL-1) plays a key role in triggering the intense inflammation during gout attacks. When uric acid crystals accumulate in joints, they activate the immune system, which releases IL-1. This molecule then recruits white blood cells to the area, causing the characteristic pain, swelling, and redness of a gout flare.
Clinical trials have tested medications called interleukin inhibitors that block IL-1 from causing inflammation. One such drug is canakinumab (Ilaris), a monoclonal antibody that specifically binds to IL-1 beta and neutralizes its effects. In clinical studies, canakinumab has shown effectiveness in treating acute gout flares in patients who cannot tolerate or don't respond well to NSAIDs, colchicine, or corticosteroids. The medication is given as a subcutaneous injection. While it represents an alternative for difficult-to-treat cases, its use remains limited due to cost and the availability of other effective treatments. Canakinumab is primarily considered for patients with contraindications to standard therapies or when standard treatments have failed to provide adequate relief.
Beyond improving anti-inflammatory treatments, researchers are also working on new ways to lower uric acid levels. Some clinical trials are exploring combinations of existing medications to see if using two or more urate-lowering drugs together works better than using one alone. Other studies are investigating whether adding medications that enhance the breakdown of uric acid alongside medications that reduce its production might achieve better control of blood uric acid levels.
Trials are also examining whether certain immunosuppressive medications used in combination with pegloticase can prevent the development of antibodies against the drug. When patients develop antibodies to pegloticase, it becomes less effective over time. If researchers can find ways to prevent this immune response, more patients might benefit from this powerful uric acid-lowering treatment for longer periods.
Clinical trials for gout treatments progress through several phases, each with a specific purpose. Phase I trials involve a small number of healthy volunteers or patients and focus primarily on safety. Researchers determine appropriate doses and identify potential side effects. These trials don't typically assess whether the treatment actually works to relieve gout symptoms or lower uric acid.
Phase II trials include more participants and begin to evaluate whether the treatment is effective. For gout, this might mean measuring how well a new medication reduces pain during an acute attack or how much it lowers uric acid levels. Phase II studies help researchers understand the optimal dose and whether the treatment shows enough promise to warrant larger, more expensive studies. These trials also continue to monitor safety in a larger group of patients.
Phase III trials are large studies that compare the new treatment to current standard treatments or placebo. These trials provide the strongest evidence about whether a new therapy is effective and safe. They typically involve hundreds or thousands of patients and take place at multiple medical centers, sometimes in different countries. For gout medications, Phase III trials measure outcomes like the number of gout flares over time, pain scores, ability to achieve target uric acid levels, and side effects. If a medication successfully completes Phase III trials and shows it's safe and effective, the manufacturer can apply for regulatory approval from agencies like the U.S. Food and Drug Administration or the European Medicines Agency.
Phase IV trials, also called post-marketing studies, take place after a medication has been approved and is available for doctors to prescribe. These studies continue to monitor long-term safety and effectiveness in larger, more diverse populations. They might also explore new uses for the medication or compare it to other treatments that weren't included in earlier trials.
Gout clinical trials take place in medical centers around the world, including in the United States, Europe, and other regions. Many trials are conducted at multiple sites simultaneously to recruit enough participants more quickly. Patients interested in participating in a clinical trial can search for studies through online databases that list current trials by condition and location. Eligibility criteria vary depending on the study, but generally participants need to have confirmed gout, meet certain disease severity requirements, and not have conditions that would make participation unsafe.
This guide is here to help you understand the condition. It does not replace a conversation with your doctor, who knows your situation best.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
